发布求助
文献互助 智能选刊 最新文献

[Rinsho ketsueki] The Japanese journal of clinical hematology最新文献

筛选
英文 中文
[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2025-01-01 DOI: 10.11406/rinketsu.66.303
{"title":"","authors":"","doi":"10.11406/rinketsu.66.303","DOIUrl":"https://doi.org/10.11406/rinketsu.66.303","url":null,"abstract":"","PeriodicalId":93844,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"66 5","pages":"303-304"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144227919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[CAR T-cell therapy and bispecific antibodies for relapsed/refractory follicular lymphoma]. CAR - t细胞疗法和双特异性抗体治疗复发/难治性滤泡性淋巴瘤。
[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2025-01-01 DOI: 10.11406/rinketsu.66.424
Shinichi Makita
{"title":"[CAR T-cell therapy and bispecific antibodies for relapsed/refractory follicular lymphoma].","authors":"Shinichi Makita","doi":"10.11406/rinketsu.66.424","DOIUrl":"10.11406/rinketsu.66.424","url":null,"abstract":"<p><p>Follicular lymphoma (FL) is the second most common lymphoma subtype diagnosed in Japan. Although FL is not curable, it generally has an indolent clinical course in the absence of histologic transformation to aggressive B-cell lymphoma. However, subsets of patients, including those with progression of disease within 24 months (POD24) and those refractory to rituximab and/or alkylators, have a worse prognosis when treated with conventional cytotoxic chemotherapies. Currently, several novel immunotherapies including chimeric antigen receptor (CAR) T-cell therapy and bispecific antibody (BsAb) therapy are under development for the treatment of B-cell non-Hodgkin lymphomas. Several randomized studies in relapsed/refractory diffuse large B-cell lymphoma have already demonstrated the superiority of novel immunotherapies over cytotoxic chemotherapy. Several single-arm pivotal studies of CAR T-cell therapies and BsAb therapies for relapsed/refractory FL have been conducted recently. Some of these agents have already been approved for the treatment of relapsed/refractory FL and are changing clinical practice dramatically. This manuscript summarizes available clinical data on CAR T-cell therapy and BsAb therapy for FL and briefly discusses future prospects.</p>","PeriodicalId":93844,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"66 6","pages":"424-431"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144577203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Overview]. (概述)。
[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2025-01-01 DOI: 10.11406/rinketsu.66.464
Yoshitaka Miyakawa
{"title":"[Overview].","authors":"Yoshitaka Miyakawa","doi":"10.11406/rinketsu.66.464","DOIUrl":"https://doi.org/10.11406/rinketsu.66.464","url":null,"abstract":"","PeriodicalId":93844,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"66 6","pages":"464"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144577214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2025-01-01 DOI: 10.11406/rinketsu.66.874
{"title":"","authors":"","doi":"10.11406/rinketsu.66.874","DOIUrl":"https://doi.org/10.11406/rinketsu.66.874","url":null,"abstract":"","PeriodicalId":93844,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"66 8","pages":"874"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144994685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Epigenetic dysregulation driving multiple myeloma]. [表观遗传失调驱动多发性骨髓瘤]。
[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2025-01-01 DOI: 10.11406/rinketsu.66.645
Hiroto Ohguchi
{"title":"[Epigenetic dysregulation driving multiple myeloma].","authors":"Hiroto Ohguchi","doi":"10.11406/rinketsu.66.645","DOIUrl":"https://doi.org/10.11406/rinketsu.66.645","url":null,"abstract":"<p><p>Multiple myeloma (MM) is triggered and promoted by the accumulation of genetic alterations. However, MM is highly dependent on the bone marrow microenvironment, which suggests that epigenetic deregulation plays a significant role in the pathogenesis of MM. Indeed, recent studies using next-generation sequencing have revealed epigenetic alterations in MM. Epigenetic regulation involved in the development of cancers, including MM, can either be observed across multiple cancer types or be specific to a single cancer type. The former type of regulation is associated with driver events common to multiple cancer types, and my colleagues and I have recently identified the importance of the KDM5A-mediated H3K4 methylation cycle in activating MYC-driven transcription. The latter type is closely related to lineage-restricted epigenetic programs. In MM, the B-cell differentiation factor IL-6 may partly mediate the MM-distinct epigenetic program. This article discusses epigenetic deregulation in MM, focusing on our recent findings.</p>","PeriodicalId":93844,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"66 7","pages":"645-650"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144796379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Overview]. (概述)。
[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2025-01-01 DOI: 10.11406/rinketsu.66.546
Fumihiro Ishida
{"title":"[Overview].","authors":"Fumihiro Ishida","doi":"10.11406/rinketsu.66.546","DOIUrl":"https://doi.org/10.11406/rinketsu.66.546","url":null,"abstract":"","PeriodicalId":93844,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"66 7","pages":"546"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144796387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Successful treatment with cyclosporine for central nervous system disorder caused by Epstein-Barr virus meningitis in other iatrogenic immunodeficiency-associated lymphoproliferative disorder]. [环孢素成功治疗其他医源性免疫缺陷相关淋巴细胞增生性疾病中Epstein-Barr病毒性脑膜炎引起的中枢神经系统疾病]。
[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2025-01-01 DOI: 10.11406/rinketsu.66.541
Makoto Nishijima, Naonori Harada, Kumiyo Tazoe, Yusuke Kizawa, Hiroshi Siragami, Atsuko Mugitani
{"title":"[Successful treatment with cyclosporine for central nervous system disorder caused by Epstein-Barr virus meningitis in other iatrogenic immunodeficiency-associated lymphoproliferative disorder].","authors":"Makoto Nishijima, Naonori Harada, Kumiyo Tazoe, Yusuke Kizawa, Hiroshi Siragami, Atsuko Mugitani","doi":"10.11406/rinketsu.66.541","DOIUrl":"https://doi.org/10.11406/rinketsu.66.541","url":null,"abstract":"<p><p>Methotrexate-associated lymphoproliferative disorder (MTX-LPD) with central nervous system (CNS) disorder caused by Epstein-Barr virus (EBV) infection is very rare. We report a case of other iatrogenic immunodeficiency-associated lymphoproliferative disorder (OII-LPD) with EBV meningitis in an 83-year-old woman. She was diagnosed with rheumatoid arthritis and treated with MTX for 10 years. She was referred to our hospital for admission due to fever and weakness that started in early May 2024 and 27% atypical lymphocytes in her peripheral blood. On the third day of hospitalization, she developed a consciousness disorder with JCS I-3 and myoclonus-like involuntary movements. Treatment with cyclosporine was initiated after detection of an elevated EBV-DNA level in her peripheral blood on the 10th day, and her consciousness level markedly improved that day. Later, EBV was detected in the cerebrospinal fluid and was found to have infected her B cells. This case demonstrates that cyclosporine, which selectively suppresses T cell activation due to EBV infection, could be effective as an initial treatment for patients who are not good candidates for chemotherapy due to age, general condition, or CNS disorders.</p>","PeriodicalId":93844,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"66 7","pages":"541-545"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144796391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Disseminated intravascular coagulation associated with solid cancers]. [与实体癌相关的弥散性血管内凝血]。
[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2025-01-01 DOI: 10.11406/rinketsu.66.833
Yoshinobu Seki
{"title":"[Disseminated intravascular coagulation associated with solid cancers].","authors":"Yoshinobu Seki","doi":"10.11406/rinketsu.66.833","DOIUrl":"10.11406/rinketsu.66.833","url":null,"abstract":"<p><p>Disseminated intravascular coagulation (DIC) is a cancer-associated paraneoplastic syndrome. Solid cancers typically present with a clinical form of chronic DIC in which thrombocytopenia due to hypercoagulable activation is balanced with platelet production in the bone marrow over an extended period. Certain disseminated cancers also present with rapid-onset, severe DIC. Additionally, as a cancer-associated thrombosis (CAT), DIC is characterized by a hypercoagulable state, frequently leading to pathological thromboses such as deep vein thrombosis, pulmonary embolism, or cerebral infarction. If DIC is not diagnosed and treated promptly and appropriately, it can significantly worsen prognosis and quality of life in cancer patients. Therefore, it is essential to consider DIC during the routine clinical management of solid cancers. This review discusses the pathogenesis of DIC associated with solid cancers, as well as diagnostic methods and treatment methods and principles based on the recently published Clinical Practice Guidelines for management of DIC in Japan 2024 by the Japanese Society on Thrombosis and Hemostasis.</p>","PeriodicalId":93844,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"66 8","pages":"833-841"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144994568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[New mechanisms and therapeutic targets for viral tumors]. [病毒性肿瘤的新机制和治疗靶点]。
[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2025-01-01 DOI: 10.11406/rinketsu.66.998
Ai Kotani
{"title":"[New mechanisms and therapeutic targets for viral tumors].","authors":"Ai Kotani","doi":"10.11406/rinketsu.66.998","DOIUrl":"https://doi.org/10.11406/rinketsu.66.998","url":null,"abstract":"<p><p>Virus-related cancers remain a notable subset of all cancers, and many are still difficult to control, despite the fact that most infectious diseases other than emerging infectious ones can now be controlled. Among these, Epstein-Barr virus (EBV)-associated cancers, which are less common in the West and more common in East Asia, have a particularly poor prognosis. Due to the low frequency of EBV-associated cancers in Europe and the United States, little progress has been made in research and development for new drugs specific to these cancers, making drugs from East Asia essential for improving prognosis. This article focuses on EBV-associated cancers of hematopoietic origin, and describes the current status of various novel therapies, as well as the anti-transferrin antibody for aggressive NK leukemia developed by the author.</p>","PeriodicalId":93844,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"66 9","pages":"998-1003"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145208692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Fertility preservation in hematopoietic cell transplantation: focusing on female patients]. [造血细胞移植中的生育能力保存：以女性患者为重点]。
[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2025-01-01 DOI: 10.11406/rinketsu.66.1191
Masahiro Ashizawa, Yoshinobu Kanda
{"title":"[Fertility preservation in hematopoietic cell transplantation: focusing on female patients].","authors":"Masahiro Ashizawa, Yoshinobu Kanda","doi":"10.11406/rinketsu.66.1191","DOIUrl":"https://doi.org/10.11406/rinketsu.66.1191","url":null,"abstract":"<p><p>Advancements in hematopoietic cell transplantation (HCT) have enabled long-term survival for young patients with hematologic disorders. However, addressing infertility caused by gonadal dysfunction remains a significant challenge. Since myeloablative conditioning regimens often destroy gonadal function completely, collaborating with reproductive medicine specialists from the pre-treatment stage is essential to determine the appropriate timing for fertility preservation. Domestic and international guidelines on fertility preservation have recently been updated, and measures for fertility preservation in patients undergoing high-risk treatments, including HCT, are currently being developed. However, cases of successful pregnancy and childbirth using assisted reproductive technology after HCT remain rare. This article offers an overview of gonadal toxicity related to HCT, the indications and limitations of fertility preservation methods, the effectiveness of ovarian shielding, and the safety and risks of pregnancy and childbirth following HCT. It also outlines practical approaches for achieving pregnancy and childbirth in HCT patients in clinical practice.</p>","PeriodicalId":93844,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"66 9","pages":"1191-1202"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145208749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信